257 results match your criteria: "Osteoncology & Rare Tumors Center[Affiliation]"

In orthopedics, the use of anti-infective biomaterials is considered the most promising strategy to contrast the bacterial contamination of implant surfaces and reduce the infection rate. KSL, KSL-W, and Dadapin-1 are three antimicrobial peptides (AMPs) that possess significant antibacterial properties, making them promising candidates for producing anti-infective biomaterials not based on antibiotics. To fully assess their true potential, this study explores in detail their cytocompatibility on human osteoblast-like MG63 cells, murine fibroblastoid L929 cells, and hMSCs.

View Article and Find Full Text PDF

Exploring nanotechnology solutions for improved outcomes in gastrointestinal stromal tumors.

Heliyon

December 2024

Preclinic and Osteoncology Unit, Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014, Meldola, Italy.

Objectives: Gastrointestinal stromal tumors, the most prevalent mesenchymal tumors (80 %) of the gastrointestinal tract, comprise less than 1 % of all gastrointestinal neoplasms and about 5 % of all sarcomas. Despite their rarity, Gastrointestinal stromal tumors present diverse clinical manifestations, anatomic locations, histological subtypes, and prognostic outcomes.

Methods: This scoping review comprehensively explores the epidemiology, clinical characteristics, diagnostic and prognostic modalities, as well as new therapeutic options for Gastrointestinal stromal tumors.

View Article and Find Full Text PDF

Biliary tract cancers (BTCs) are aggressive neoplasms with limited therapeutic options. The amount of prospective evidence is poor, and limited data are available on the impact of treatment sequencing on survival. Here we report a real-world experience of patients with advanced BTC treated with at least three lines of therapy.

View Article and Find Full Text PDF

Fatigue Syndrome in Patients with Bone and Soft Tissue Sarcomas: An Observational Study.

Semin Oncol Nurs

December 2024

IRCCS Istituto Ortopedico Rizzoli, Servizio di Assistenza Infermieristico, Tecnico e della Riabilitazione (SAITeR), Bologna, Italy.

Objectives: The aim of the present study is to describe the course of fatigue syndrome in patients with musculoskeletal tumors starting from chemotherapy and to compare it with that of other cancer populations. The second objective is to identify the risk factors for a higher level of fatigue.

Methods: A prospective prognostic observational cohort study was carried out.

View Article and Find Full Text PDF

High-grade osteosarcoma (OS) is the most common primary bone tumor mainly affecting children and young adults. First-line treatment consists of neo-adjuvant chemotherapy with doxorubicin, cisplatin, and methotrexate and surgery. The mean long-term survival rate for localized disease at diagnosis is 65-70%, dropping down to 20% when metastases are present at diagnosis.

View Article and Find Full Text PDF

Background: Herein, we present the results of the phase 2 IMMUNOSARC study (NCT03277924), investigating sunitinib and nivolumab in adult patients with advanced bone sarcomas (BS).

Methods: Progressing patients with a diagnosis of BS were eligible. Treatment was comprised of sunitinib (37.

View Article and Find Full Text PDF

Possible role of bone turnover markers in the diagnosis of adult hypophosphatasia.

J Bone Miner Res

December 2024

Clinica Medica 1, Department of Medicine, University of Padua, European Reference Network on Rare Bone Diseases (ERN BOND), 35128 Padova, Italy.

Hypophosphatasia (HPP) is a rare disorder of the bone metabolism, characterized by genetically determined low alkaline phosphatase (ALP) activity. Low ALP may also be observed in some common causes of bone fragility, such as in osteoporosis treated with antiresorptive drugs. This study aimed to verify whether differences in bone turnover markers (BTMs) could help differentiate adult patients with HPP from those with osteoporosis undergoing antiresorptive treatment.

View Article and Find Full Text PDF

Proximal and Classic Epithelioid Sarcomas are Distinct Molecular Entities Defined by MYC/GATA3 and SOX17/Endothelial Markers, Respectively.

Mod Pathol

January 2025

Unit of Oncogenetics and Functional Oncogenomics, Centro di Riferimento Oncologico di Aviano (CRO Aviano) IRCCS, National Cancer Institute, Aviano, Italy. Electronic address:

Epithelioid sarcoma (ES) is a rare tumor hallmarked by the loss of INI1/SMARCB1 expression. Apart from this alteration, little is known about the biology of ES. Despite recent advances in treatment, the prognosis of ES remains unsatisfactory.

View Article and Find Full Text PDF

The aim of the study was to report the outcome of primary localized low-grade fibromyxoid sarcoma (LGFMS), sclerosing epithelioid fibrosarcoma (SEF), and hybrid LGFMS/SEF (H-LGFMS/SEF). Patients with primary localized LGFMS, SEF, or H-LGFMS/SEF, surgically treated with curative intent from January 2000 to September 2022, were enrolled from 14 countries and 27 institutions. Pathologic inclusion criteria were predefined by expert pathologists.

View Article and Find Full Text PDF

Treatment options for intrahepatic cholangiocarcinoma (iCCA), a highly malignant tumor with poor prognosis, are limited. Recent developments in immunotherapy and immune checkpoint inhibitors (ICIs) have offered new hope for treating iCCA. However, several issues remain, including the identification of reliable biomarkers of response to ICIs and immune-based combinations.

View Article and Find Full Text PDF

Purpose: The longest diameter (LD) is a strong prognostic factor for patients with soft-tissue sarcoma (STS). Other dimensional assessments, such as the sum of diameters (SoD), product of diameters (PoD), and volume (3D-COG - proposed by the Children Oncology Group), can be rapidly performed; however, their prognostic values have never been compared to LD. Our goal was to investigate their performance in improving patients' prognostication for STS of the lower limbs.

View Article and Find Full Text PDF

Imaging of Osteosarcoma: Presenting Findings, Metastatic Patterns, and Features Related to Prognosis.

J Clin Med

September 2024

Diagnostic and Interventional Radiology, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy.

Article Synopsis
  • Osteosarcomas are rare bone tumors that make up less than 1% of all cancers and are most commonly found in children, second only to multiple myeloma among primary bone tumors.
  • The imaging characteristics of osteosarcomas vary by histological subtype, with conventional types showing mixed radiological patterns and aggressive features, while telangiectatic forms are typically purely lytic.
  • The review emphasizes the relationship between imaging features and patient outcomes, including treatment response and survival, highlighting important parameters for medical professionals involved in the management of these tumors.
View Article and Find Full Text PDF

Lipids and adipocytes involvement in tumor progression with a focus on obesity and diet.

Obes Rev

December 2024

Preclinic and Osteoncology Unit, Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.

Article Synopsis
  • Adipose tissue, or body fat, is more than just a fat store; it helps in cancer growth by providing energy and sending signals that promote tumor activity.
  • Cancer can make fat cells act differently, which creates a cycle that helps the tumor grow even more.
  • The review also talks about how being obese can increase cancer risks and how different diets can influence cancer's development and new treatments for it.
View Article and Find Full Text PDF

Osteosarcoma is a highly aggressive primary bone tumor that has seen little improvement in survival rates in the past three decades. Preclinical studies are conducted on a small pool of commercial cell lines which may not fully reflect the genetic heterogeneity of this complex cancer, potentially hindering translatability of results. Developing a single-site laboratory protocol to rapidly establish patient-derived primary cancer cell lines (PCCL) within a clinically actionable time frame of a few weeks will have significant scientific and clinical ramifications.

View Article and Find Full Text PDF

Xenografting Human Musculoskeletal Sarcomas in Mice, Chick Embryo, and Zebrafish: How to Boost Translational Research.

Biomedicines

August 2024

Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies Unit, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy.

Article Synopsis
  • Musculoskeletal sarcomas are rare and diverse tumors, making research and treatment challenging for scientists and healthcare providers.
  • Traditional methods using mice for xenografting are increasingly limited due to ethical concerns and stricter regulations, leading researchers to seek alternative models like chick embryos and zebrafish.
  • These alternative models offer benefits such as cost-effectiveness, ease of tracking tumor growth, and the potential for enhanced drug screening, suggesting that a combination of different models could improve research and understanding of these tumors.
View Article and Find Full Text PDF
Article Synopsis
  • * The study utilized in silico analysis and tested various sarcoma cell lines in the lab (in vitro) and in a mouse model (in vivo) to identify ways to enhance the effectiveness of trabectedin.
  • * Researchers found that a specific druggable target, Glo1, increases after trabectedin treatment and that the Glo1 inhibitor BBGC boosts trabectedin's effectiveness and restores sensitivity in resistant cells without harming mice.
View Article and Find Full Text PDF

Background: Tenosynovial giant cell tumor (TGCT) is a rare, locally aggressive tumor of the joints, bursa, and tendon sheath that can cause considerable pain and substantial morbidity. Although surgery is the primary treatment for patients with TGCT, surgical resection is associated with high rates of recurrence, particularly for patients with diffuse TGCT. Pexidartinib, a colony-stimulating factor 1 receptor inhibitor, is approved by the US Food and Drug Administration for the treatment of adult patients with symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery.

View Article and Find Full Text PDF

Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up.

J Nucl Med

September 2024

Nuclear Medicine and Radiometabolic Units, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Meldola, Italy.

Recurrence of meningiomas after surgery and radiotherapy deserves specific attention because of the lack of active third-line therapies. Somatostatin receptors are usually overexpressed on the cell membrane of meningiomas, and this has led the way to a radionuclide theranostic approach. Diagnoses with Ga-DOTA-octreotide and peptide receptor radionuclide therapy (PRRT) with Y/Lu-DOTA-octreotide are currently possible options within experimental protocols or as compassionate use in small patient groups.

View Article and Find Full Text PDF

Surgical treatment of aneurysmal bone cysts (ABCs) can be challenging, especially in the spine. Non-surgical treatments such as with denosumab have shown promising results in different osteolytic pathologies. This retrospective observational study aimed to evaluate the long-term clinical and radiologic response of patients with ABCs of the mobile spine treated with denosumab and propose an updated treatment algorithm.

View Article and Find Full Text PDF

Role of CDK4 as prognostic biomarker in Soft Tissue Sarcoma and synergistic effect of its inhibition in dedifferentiated liposarcoma sequential treatment.

Exp Hematol Oncol

August 2024

Preclinic and Osteoncology Unit, Biosciences Laboratory, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) "Dino Amadori", Meldola, FC, Italy.

Article Synopsis
  • Soft tissue sarcomas make up a rare group of tumors accounting for just 1% of solid cancers, with liposarcoma being a notable subtype.
  • The study focused on 21 patients with atypical lipomatous tumors/well differentiated liposarcoma (ALT/WDLPS) and dedifferentiated liposarcoma (DDLPS), investigating the role of biomarkers CDK4 and MDM2.
  • Results indicated that CDK4 was more highly expressed in DDLPS than in ALT/WDLPS, and the CDK4 inhibitor palbociclib showed promise in a sequential treatment approach when combined with lenvatinib, suggesting a new management strategy for DDLPS.
View Article and Find Full Text PDF

Introduction: Extraskeletal Ewing sarcoma (EEwS) is a rare malignant tumor, and current international recommendations indicate systemic and local treatment like bone Ewing sarcoma (BEwS); to the best of our knowledge, very few studies tried to explore the clinical and genetic characteristics of this tumor, and the most appropriate treatment strategy remains uncertain.

Methods: We reviewed 35 EEwS cases enrolled at Rizzoli Orthopedic Institute in Bologna, Italy, between 1988-2022. We performed RNA sequencing in 18 Ewing sarcoma cases, including 12 BEwSs and 6 EEwSs.

View Article and Find Full Text PDF

Adverse skeletal related events in patients with bone-metastatic pheochromocytoma/paraganglioma.

Eur J Cancer

September 2024

Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, ASST Spedali Civili, Brescia, Italy.

Metastatic pheochromocytomas and paragangliomas (PPGLs) are frequently associated with skeletal complications. Primary objective: to describe the frequency of adverse skeletal related events (SREs) in PPGL patients with bone metastases (BMs). Secondary objectives: to 1) identify predictive and prognostic factors for SREs and 2) obtain information on the effectiveness of bone resorption inhibitors in reducing SRE risk and improving outcomes in term of survival and SREs time onset.

View Article and Find Full Text PDF

Spatial distribution of tumour immune infiltrate predicts outcomes of patients with high-risk soft tissue sarcomas after neoadjuvant chemotherapy.

EBioMedicine

August 2024

Sarcoma Service, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy. Electronic address:

Article Synopsis
  • - The study analyzed how anthracycline-based neoadjuvant chemotherapy (NAC) affects immune cells' spatial distribution in high-risk soft tissue sarcomas (STS) and how this relates to patient outcomes.
  • - Researchers examined various tumor areas for specific immune cells using advanced pathology techniques and created a sarcoma immune index (SIS) to predict disease-free and overall survival rates.
  • - Findings revealed that certain immune cell types, particularly PD-1+ and CD20+ B-cells, correlated with prognosis differently based on their locations within the tumor, highlighting NAC's role in altering tumor immune characteristics.
View Article and Find Full Text PDF

A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas.

Eur J Cancer

September 2024

Osteoncology and Rare Tumor Center (CDO-TR), IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy; Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies Unit, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.

Background: Neuroendocrine Carcinomas (NECs) prognosis is poor.No standard second-line therapy is currently recognized after failure of platinum-based first-line treatment. FOLFIRI and CAPTEM regimens have shown promising activity in preliminary studies.

View Article and Find Full Text PDF

Clinical and translational implications of immunotherapy in sarcomas.

Front Immunol

July 2024

Preclinic and Osteoncology Unit, Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.

Article Synopsis
  • Immunotherapy is becoming an important treatment for sarcomas, which are tumors that can act very differently from each other.
  • Researchers found that understanding the different immune environments in these tumors can help improve treatment results.
  • The presence of specific immune cells called Tumor Infiltrating Lymphocytes (TIL) may help patients live longer and respond better to immunotherapy, along with certain genes related to the immune system.
View Article and Find Full Text PDF